Proportions achieving a hemagglutination inhibition antibody ( HIA ) titer of 40 or higher at 21 days after the second vaccination ; vaccine-related serious adverse events through 12 months after the first vaccination ; and solicited signs and symptoms after vaccination through day 7 .